Creative Medical Technology (NASDAQ:CELZ) Posts Earnings Results, Hits Expectations

Creative Medical Technology (NASDAQ:CELZ) announced its quarterly earnings results on Friday. The company reported ($0.48) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.48), Zacks reports.

Creative Medical Technology Trading Up 1.7%

CELZ stock traded up $0.05 during mid-day trading on Friday, reaching $3.02. The company’s stock had a trading volume of 170,960 shares, compared to its average volume of 145,810. Creative Medical Technology has a 12 month low of $1.69 and a 12 month high of $6.90. The business’s 50 day moving average price is $3.51 and its 200 day moving average price is $2.88.

Analyst Ratings Changes

Several research firms have recently commented on CELZ. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Creative Medical Technology in a research report on Wednesday. Wall Street Zen raised shares of Creative Medical Technology to a “sell” rating in a report on Saturday, August 9th. Finally, Zacks Research raised Creative Medical Technology to a “hold” rating in a report on Tuesday, August 12th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce”.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.